CD49d expression identifies a biologically distinct subtype of chronic lymphocytic leukemia with inferior progression-free survival on BTK inhibitor therapy.

Anfal Alsadhan Jonathan Chen Erika M Gaglione Chingiz Underbayev Pamela L Tuma Xin Tian Lita A Freeman Sivasubramanian Baskar Pia Nierman Susan Soto Andy Itsara Inhye E Ahn Clare Sun Elena Bibikova Tanja Nicole Hartmann Maissa Mhibik Adrian Wiestner

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

CD49d/VLA-4 emerges as a microenvironmental factor that contributes to BTKi resistance in CLL. The prognostic value of CD49d is improved by considering bimodal CD49d expression.

Keyphrases

chronic lymphocytic leukemia
poor prognosis
free survival
nk cells
tyrosine kinase
stem cells
mesenchymal stem cells
bone marrow